drugset
Drugs / MELITAC 12.1 Peptide Vaccine
last change May 2017 re-read 2 minutes ago

MELITAC 12.1 Peptide Vaccine

Vaccine

Developed for
cutaneous melanoma · mucosal melanoma · uveal melanoma
Investigated by
Fred Hutchinson Cancer Center · Incyte Corporation · National Cancer Institute (NCI) · University of Virginia

Trials 1 · a red edge is where a trial was stopped

today NCT01961115 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01961115 Sep 2013 → Oct 2016 cutaneous melanoma, mucosal melanoma, uveal melanoma Fred Hutchinson Cancer Center Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MELITAC 12.1 Peptide Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01961115 ↗
Modality Vaccine “multipeptide melanoma vaccine” NCT01961115 ↗
Route Other “receive MELITAC 12.1 peptide vaccine intradermally (ID)/subcutaneously (SC)” NCT01961115 ↗
Route Subcutaneous “receive MELITAC 12.1 peptide vaccine intradermally (ID)/subcutaneously (SC)” NCT01961115 ↗